TESAMORELIN

Tesamorelin is a peptide studied in clinical research for its activity within the growth hormone-releasing hormone (GHRH) pathway and its effects on growth hormone signaling and metabolic processes. DeSoto Peptides supplies Tesamorelin as a lyophilized research material with batch-specific documentation available for verification.

Illustration of a vaccine vial with a blue cap and a medical cross on the label.

2/5/10MG PER VIAL

Lyophilized research material

Digital icon of a microscope with blue and white colors on a black background.

RESEARCH GRADE

Lot-specific documentation available

Blue and white shield with a check mark in the center, symbolizing security or protection.

BATCH VERIFIED

For laboratory research only

ONE SIGNAL. A CONNECTED RESEARCH PATHWAY.

GROWTH HORMONE SIGNALING RESEARCH

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) studied for its activity within the growth hormone signaling pathway. Research has examined how GHRH receptor activation influences downstream growth hormone and IGF-1 signaling, as well as associated metabolic processes.

Neon blue glowing sign with the text "GHRH" above a molecular structure of a peptide or hormone on a black background.
Neon purple illustration of a molecular structure with the text 'Growth Hormone' above it.

Pituitary signaling
GHRH receptor activation
Growth hormone release

Downstream signaling
Metabolic regulation
Body-composition research

Digital illustration of the IGF-1 hormone with a molecular structure and glowing green text 'IGF-1' against a black background.

GH-mediated signaling
Cellular growth pathways
Metabolic processes

WHAT THE RESEARCH SHOWS

Clinical research has evaluated tesamorelin's effects on visceral adipose tissue, growth hormone signaling, IGF-1, and metabolic measures.

Bar chart showing change in visceral adipose tissue after 26 weeks for two groups: tesamorelin, with a decrease of -15.2%, and placebo, with an increase of 5.0%.

Randomized controlled research demonstrated a significant reduction in visceral adipose tissue over 26 weeks compared with placebo

Digital display showing a 15.2% decrease in visceral fat at 26 weeks.
Neon-style graphic displaying '26 WEEKS' in large blue font, with 'RANDOMIZED STUDY' and 'Participants with excess body abdominal fat' in smaller white and blue fonts, and 'N=412' at the bottom.
Neon sign displaying the logo of The New England Journal of Medicine in black and white with blue outline.
Neon sign indicating peer-reviewed article from the New England Journal of Medicine, citing Falutz J, et al., published in 2007.
A digital citation bubble displaying a scientific article reference about Tasemorelin reducing excess abdominal fat in HIV-infected patients, with the citation: Lancet, 2002; 359: 2072-2078.
A digital citation bubble displaying a scientific article reference about Tasemorelin reducing excess abdominal fat in HIV-infected patients, with the citation: Lancet, 2002; 359: 2072-2078.

TESAMORELIN 2/5/10MG

Research material with batch-specific documentation.

Learn More About Tesamorelin
Contact Us

For research use only. Not for human consumption